NAS:VTVT (USA) Also trade in: Germany

vTv Therapeutics Inc

$ 1.4 -0.01 (-0.71%)
Volume: 92,873 Avg Vol (1m): 808,938
Market Cap $: 75.79 Mil Enterprise Value $: 84.01 Mil
P/E (TTM): 0.00 P/B: 0.00
Earnings Power Value -280.7
Net Current Asset Value -2.76
Tangible Book -2.53
Projected FCF 0
Median P/S Value 50.88
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 2/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.38
Cash-To-Debt range over the past 10 years
Min: 0.01, Med: 0.6, Max: 10000
Current: 0.38
0.01
10000
Equity-to-Asset -5.38
Equity-to-Asset range over the past 10 years
Min: -38.52, Med: -4.67, Max: -0.79
Current: -5.38
-38.52
-0.79
Debt-to-Equity -0.23
Debt-to-Equity range over the past 10 years
Min: -0.41, Med: -0.15, Max: -0.07
Current: -0.23
-0.41
-0.07
Debt-to-EBITDA -0.91
Debt-to-EBITDA range over the past 10 years
Min: -2.36, Med: -0.78, Max: -0.2
Current: -0.91
-2.36
-0.2
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -32.78
DISTRESS
GREY
SAFE
Beneish M-Score 8.90
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC -24.58%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -132.65
Operating Margin range over the past 10 years
Min: -17416.49, Med: -5510.27, Max: -132.65
Current: -132.65
-17416.49
-132.65
Net Margin % -63.01
Net Margin range over the past 10 years
Min: -5547.77, Med: -3759.01, Max: -63.01
Current: -63.01
-5547.77
-63.01
ROA % -63.14
ROA range over the past 10 years
Min: -310.91, Med: -48.01, Max: -22.4
Current: -63.14
-310.91
-22.4
ROC (Joel Greenblatt) % -9711.44
ROC (Joel Greenblatt) range over the past 10 years
Min: -13962.86, Med: -6039.11, Max: -628.78
Current: -9711.44
-13962.86
-628.78
3-Year Total Revenue Growth Rate 188.30
3-Year Revenue Growth Rate range over the past 10 years
Min: -46.7, Med: -19.2, Max: 151.2
Current: 151.2
-46.7
151.2
3-Year Total EBITDA Growth Rate 19.70
3-Year EBITDA Growth Rate range over the past 10 years
Min: -11.7, Med: -8.2, Max: 29.9
Current: 29.9
-11.7
29.9
3-Year EPS w/o NRI Growth Rate 40.80
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -22.9, Max: 40.8
Current: 40.8
0
40.8

» VTVT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:VTVT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare AMEX:PFNX NAS:FWP NAS:ACER NAS:MDWD XKRX:041910 XCNQ:THC TPE:1786 LSE:BVXP NAS:EVFM NAS:CDMO NAS:CKPT XKRX:043090 TSE:7776 OSL:PCIB OTCPK:RASP NAS:CFRX XTER:CNWK NAS:PSTI OTCPK:ARPO LSE:TRX
Traded in other countries 5VT.Germany
Address 4170 Mendenhall Oaks Parkway, High Point, NC, USA, 27265
vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as the Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Ratios

Current vs industry vs history
PS Ratio 1.75
PS Ratio range over the past 10 years
Min: 1.02, Med: 62.35, Max: 777
Current: 1.75
1.02
777
EV-to-EBIT -5.50
EV-to-EBIT range over the past 10 years
Min: -6.17, Med: -2.7, Max: -0.4
Current: -5.5
-6.17
-0.4
EV-to-EBITDA -5.58
EV-to-EBITDA range over the past 10 years
Min: -6.25, Med: -2.7, Max: -0.5
Current: -5.58
-6.25
-0.5
EV-to-Revenue 7.13
EV-to-Revenue range over the past 10 years
Min: 2.8, Med: 138, Max: 2133.1
Current: 7.13
2.8
2133.1
Current Ratio 0.33
Current Ratio range over the past 10 years
Min: 0.03, Med: 0.76, Max: 16.1
Current: 0.33
0.03
16.1
Quick Ratio 0.33
Quick Ratio range over the past 10 years
Min: 0.03, Med: 0.76, Max: 16.1
Current: 0.33
0.03
16.1

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 27.60
3-Year Share Buyback Rate range over the past 10 years
Min: -61.3, Med: -61.3, Max: 27.6
Current: 27.6
-61.3
27.6

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 0.03
Price-to-Median-PS-Value range over the past 10 years
Min: 0.02, Med: 0.97, Max: 9.22
Current: 0.03
0.02
9.22
Earnings Yield (Joel Greenblatt) % -18.09
Earnings Yield (Greenblatt) range over the past 10 years
Min: -222.9, Med: -36.75, Max: -16.1
Current: -18.09
-222.9
-16.1

More Statistics

Revenue (TTM) (Mil) $ 11.29
EPS (TTM) $ -0.73
Beta -5.88
Volatility % 264.1
52-Week Range $ 0.68 - 6.09
Shares Outstanding (Mil) 54.13

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y